Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

Andrea Visentin; Francesca Romana Mauro; Francesca Cibien; Candida Vitale; Gianluigi Reda; Alberto Fresa; Stefania Ciolli; Daniela Pietrasanta; Monia Marchetti; Roberta Murru; Massimo Gentile; Gian Matteo Rigolin; Francesca Maria Quaglia; Lydia Scarfò; Paolo Sportoletti; Stefano Pravato; Francesco Piazza; Marta Coscia; Luca Laurenti; Stefano Molica; Robin Foà; Antonio Cuneo; Livio Trentin

doi:10.1002/ajh.26437

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

Andrea Visentin, Francesca Romana Mauro, Francesca Cibien, Candida Vitale, Gianluigi Reda, Alberto Fresa, Stefania Ciolli, Daniela Pietrasanta, Monia Marchetti, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin, Francesca Maria Quaglia, Lydia Scarfò, Paolo Sportoletti, Stefano Pravato, Francesco Piazza, Marta Coscia, Luca Laurenti, Stefano MolicaRobin Foà, Antonio Cuneo, Livio Trentin

Research output: Contribution to journal › Letter › peer-review

Original language	English
Pages (from-to)	E95-E99
Journal	American Journal of Hematology
Volume	97
Issue number	3
DOIs	https://doi.org/10.1002/ajh.26437
Publication status	Published - 2022

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26437

Cite this

Visentin, A., Mauro, F. R., Cibien, F., Vitale, C., Reda, G., Fresa, A., Ciolli, S., Pietrasanta, D., Marchetti, M., Murru, R., Gentile, M., Rigolin, G. M., Quaglia, F. M., Scarfò, L., Sportoletti, P., Pravato, S., Piazza, F., Coscia, M., Laurenti, L., ... Trentin, L. (2022). Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. American Journal of Hematology, 97(3), E95-E99. https://doi.org/10.1002/ajh.26437

Visentin, A, Mauro, FR, Cibien, F, Vitale, C, Reda, G, Fresa, A, Ciolli, S, Pietrasanta, D, Marchetti, M, Murru, R, Gentile, M, Rigolin, GM, Quaglia, FM, Scarfò, L, Sportoletti, P, Pravato, S, Piazza, F, Coscia, M, Laurenti, L, Molica, S, Foà, R, Cuneo, A & Trentin, L 2022, 'Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study', American Journal of Hematology, vol. 97, no. 3, pp. E95-E99. https://doi.org/10.1002/ajh.26437

@article{47a9fcb256424aa9ab281dcce4ab7caa,

title = "Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study",

author = "Andrea Visentin and Mauro, {Francesca Romana} and Francesca Cibien and Candida Vitale and Gianluigi Reda and Alberto Fresa and Stefania Ciolli and Daniela Pietrasanta and Monia Marchetti and Roberta Murru and Massimo Gentile and Rigolin, {Gian Matteo} and Quaglia, {Francesca Maria} and Lydia Scarf{\`o} and Paolo Sportoletti and Stefano Pravato and Francesco Piazza and Marta Coscia and Luca Laurenti and Stefano Molica and Robin Fo{\`a} and Antonio Cuneo and Livio Trentin",

note = "Funding Information: AV received honoraria from Janssen, Abbvie, CSL Behring, Italfarmaco. LT received research funding from Gilead, Roche, Janssen and Takeda, advisory board for Roche, Takeda, Abbvie, AstraZeneca. GMR received research funding from Gilead. FRM advisory board for Janssen, Takeda, and Abbvie. AC advisory board and speaker bureau for Roche, Abbvie, Gilead, and Janssen. RF advisory board or speaker bureau for Roche, Abbvie, Celgene, Incyte, Amgen, Janssen, Gilead, and Novartis. LL Honoraria from Abbvie, Janssen, Astra Zeneca, Beigene. FMQ Advisor role for AstraZeneca and Janssen; speaker for Janssen; consultant for Sandoz. LS received honoraria from AbbVie, AstraZeneca, and Janssen. Funding Information: This work was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) projects to LT (IG‐25024) and “Ricerca per Credere nella Vita” RCV odv. ",

year = "2022",

doi = "10.1002/ajh.26437",

language = "English",

volume = "97",

pages = "E95--E99",

journal = "American Journal of Hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "3",

}

TY - JOUR

T1 - Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia

T2 - A real-life campus CLL study

AU - Visentin, Andrea

AU - Mauro, Francesca Romana

AU - Cibien, Francesca

AU - Vitale, Candida

AU - Reda, Gianluigi

AU - Fresa, Alberto

AU - Ciolli, Stefania

AU - Pietrasanta, Daniela

AU - Marchetti, Monia

AU - Murru, Roberta

AU - Gentile, Massimo

AU - Rigolin, Gian Matteo

AU - Quaglia, Francesca Maria

AU - Scarfò, Lydia

AU - Sportoletti, Paolo

AU - Pravato, Stefano

AU - Piazza, Francesco

AU - Coscia, Marta

AU - Laurenti, Luca

AU - Molica, Stefano

AU - Foà, Robin

AU - Cuneo, Antonio

AU - Trentin, Livio

N1 - Funding Information: AV received honoraria from Janssen, Abbvie, CSL Behring, Italfarmaco. LT received research funding from Gilead, Roche, Janssen and Takeda, advisory board for Roche, Takeda, Abbvie, AstraZeneca. GMR received research funding from Gilead. FRM advisory board for Janssen, Takeda, and Abbvie. AC advisory board and speaker bureau for Roche, Abbvie, Gilead, and Janssen. RF advisory board or speaker bureau for Roche, Abbvie, Celgene, Incyte, Amgen, Janssen, Gilead, and Novartis. LL Honoraria from Abbvie, Janssen, Astra Zeneca, Beigene. FMQ Advisor role for AstraZeneca and Janssen; speaker for Janssen; consultant for Sandoz. LS received honoraria from AbbVie, AstraZeneca, and Janssen. Funding Information: This work was supported by funds from Associazione Italiana per la Ricerca sul Cancro (A.I.R.C.) projects to LT (IG‐25024) and “Ricerca per Credere nella Vita” RCV odv.

PY - 2022

Y1 - 2022

UR - http://www.scopus.com/inward/record.url?scp=85121432870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121432870&partnerID=8YFLogxK

U2 - 10.1002/ajh.26437

DO - 10.1002/ajh.26437

M3 - Letter

AN - SCOPUS:85121432870

SN - 0361-8609

VL - 97

SP - E95-E99

JO - American Journal of Hematology

JF - American Journal of Hematology

IS - 3

ER -

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this